Calidi Biotherapeutics, Inc. (United States)

Homepage: calidibio.com

Alternate names: Calidi Bio, Calidi Biotherapeutics, Calidi Biotherapeutics, Inc.

ROR: 03k8xxe54

OpenAlex ID: I4405267616

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

2020 · Lorenzo Galluzzi, Ilio Vitale, et al. · Journal for ImmunoTherapy of Cancer · 1,254

PDF

Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

2020 · Galluzzi, Lorenzo, Vitale, Ilio, et al. · Journal for ImmunoTherapy of Cancer · 156

PDF

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

2020 · Christopher J. Rogers, Robert J. Harman, et al. · Journal of Translational Medicine · 116

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

2019 · Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Davide Bedognetti, et al. · Journal for ImmunoTherapy of Cancer · 90

PDF

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

2019 · Dobrin D. Draganov, Antonio F. Santidrian, et al. · Journal of Translational Medicine · 44

PDF

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

2019 · Boris R. Minev, Elliot Lander, et al. · Journal of Translational Medicine · 37

PDF

Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses

2019 · Qiuqiang Chen, Ying Bao, et al. · Drug Delivery and Translational Research · 30

Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer

2018 · Q. Chen, L. Yao, et al. · Clinical & Translational Oncology · 15

Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy

2022 · Duong Hoang Nguyen, Thomas Herrmann, et al. · Cancers · 8

PDF

Purinergic Signaling Within the Tumor Microenvironment

2020 · Dobrin Draganov, Peter P. Lee · Advances in experimental medicine and biology · 8

Phase 1 study of multiple intracerebral doses of a neural stem cell-based oncolytic virotherapy for treatment of recurrent high-grade gliomas.

2024 · Jana Portnow, Behnam Badie, et al. · Journal of Clinical Oncology · 7

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

2019 · Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Davide Bedognetti, et al. · Journal for ImmunoTherapy of Cancer · 6

PDF

Neoadjuvant clinical trials in adults with newly diagnosed high-grade glioma: A systematic review

2024 · Tiffany M. Juarez, Jaya M. Gill, et al. · Critical Reviews in Oncology/Hematology · 2

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies

2026 · Rachael Mooney, Gary Ngai, et al. · Molecular Therapy Oncology · 1

Systemic antitumor virotherapy: Pre-clinical evaluation of tumor targeting, efficacy, and safety of lead candidate (CLD-401).

2025 · Duong Hoang Nguyen, Yunyi Kang, et al. · Journal of Clinical Oncology · 1

PDF

Non-clinical evidence supporting the upcoming CLD-201 clinical trial: Cell-based oncolytic virotherapy for multiple solid tumors.

2024 · Duong Nguyen, Ivelina Minev, et al. · Journal of Clinical Oncology · 1

Transforming tumor immune microenvironments with a novel systemic enveloped oncolytic virotherapy targeting all tumor sites.

2024 · Duong Nguyen, Yunyi Kang, et al. · Journal of Clinical Oncology · 1